Dr. Anthony Dellinger serves as President and Scientist. He has a biology background, including marine sciences. Dr. Dellinger’s expertise includes attractant molecular matter and chemistry, facilitating the invention and engineering of synthetic agents. He holds a BS in Forensic Molecular Biology with a Minor in Chemistry and a PhD in Nanoscience. He has authored or co-authored numerous peer-reviewed publications for over a decade in academia and industry. In 2015, Dellinger was named the inaugural Entrepreneur of the Year for 2015 at his alma mater, the University of North Carolina at Greensboro. Dellinger is dedicated to improving public, societal, ecological, and economic outcomes through research, inventorship and enterprise. He is member of the International Union for Conservation of Nature, Horseshoe Crab Species Specialist Group and has served as a special topic’s editor for Frontiers Journal of Marine Science and JoVE for emerging and sustainable horseshoe crab research. In addition to numerous horseshoe crab peer-reviewed scientific publications, Dellinger’s 2018 scientific review entitled, The Role of Horseshoe Crabs in the Biomedical Industry and Recent Trends Impacting Species Sustainability has achieved more 70,000 reads and is recognized as the second most viewed article published by the Frontiers Journal of Marine Sciences. The horseshoe crab work at Kepley BioSystems was featured at the 148 th Annual Academy of Fisheries Science Conference in the "Spirit in the Night: Throwing Light on Our Many Connections to the American Horseshoe Crab" symposium in Atlantic City, NJ. Dellinger was selected as a TEDxGreensboro speaker (2020) and presented emerging sustainable horseshoe crab research being performed at Kepley BioSystems (Saving the horseshoe crab and fighting the virus with nanoscience). In addition to his entrepreneurial efforts, Dellinger holds an Adjunct Professorship at the Joint School of Nanoscience and Nanoengineering and remains dedicated to shaping future STEM scientists through scholarship and invention.

Terry Brady’s 35 years of leadership experience includes global sales, marketing, invention/entrepreneurship, and executive management. Seasoned by early positions in multi nationals, including Johnson & Johnson, Richardson Vicks (purchased by Proctor and Gamble) and Union Carbide, Mr. Brady ultimately served as president of International Technidyne Corporation (ITC), Edison, NJ (now Accriva Diagnostics, San Diego, CA) and as founder, president and CEO of Array Medical, Inc., Somerville, NJ. In both roles, he led the growth and ultimate divestiture of the two companies: ITC to a Fortune 500 leader, ThermoElectron (394 in 1999); and Array to Helena Laboratories. In addressing customer needs, Mr. Brady was the lead inventor of four US patented products and numerous others with FDA-approval that remain in active commerce – many of which still enjoy segment dominance. During the first year of Array Medical operation, he conceived, developed, and conducted clinical trials for FDA approval of a major cardiovascular product. Successfully manufacturing and marketing this product through 50 worldwide dealers epitomized Mr. Brady’s mastery of traditional manufacturing operations, direction of an in-house marketing agency, and of establishing hundreds of relationships in a global dealership distribution business model.

Lee Robertson began working as a research scientist/technician with Professor Kepley at the Joint School of Nanoscience and Nanoengineering (JSNN) in 2014. He built on dual degrees in applied nanoscience technology and the humanities. Robertson has also become certified in design software, thus mastering exceptional scientific communications skills. Organizational, commercial operations, IT and sales experience also evolved earlier in his career with a major retailer, spanning nearly 16 years of sales, inventory management and supervisory roles and responsibilities. Robertson volunteered and evaluated the use of a synthetic crustacean bait at Morgan State University’s PEARL research program in the 2016-2017 and aided in the annual blue crab stock assessment program. He presented his fisheries research in China at the Duke Kunshan University in 2016 and has organized the first International Marine Ecology Symposium at Savannah State University in 2018.

Frank LaDuca is an independent consultant and adviser to the medical industry with extensive experience as a corporate officer in the medical diagnostics field. Dr. LaDuca received his doctoral degree from SUNY at Buffalo, NY, and completed a fellowship in Hematology at Johns Hopkins School of Medicine. His expertise encompasses a unique blend of regulatory, compliance, quality, clinical and technical disciplines, allowing him to master the operational issues facing companies of all sizes and to effectively address regulatory and compliance needs. He has successfully completed remediation projects, relocated medical businesses and executed product and facility registration while ensuring business continuity. He has built organizations focused on product innovation while positioning companies for optimal fiscal performance, and his teams have been recognized as “Best in Class” in their sectors. As a corporate officer, Dr. LaDuca has also managed strategic business transformation with positioning and finalization of the business for sale. At Siemens Diagnostics, he was a member of a select team of senior staff responsible for the due diligence and integration of Bayer, Diagnostic Product Corporation and Dade to Siemens Diagnostics. As the CSO member of the Accriva Diagnostics Executive Leadership Team, he provided technical and compliance guidance in its sale to Instrumentation Laboratories/Werfen. Thereafter, he established an independent regulatory, compliance and scientific consultancy to the medical industry. Dr. LaDuca has served as Chair for both the Critical and Point of Care division of the AACC and of the Clinical & Laboratory Standards Institute (CLSI) Point of Care Consensus Committee. He has authored numerous technical publications and routinely presents at national and international scientific meetings, most recently at the FDA Workshop for Standardization Guidelines for POCT Coagulation Testing (2016) - and has subsequently co-chaired the CLSI committee drafting the resulting CLSI Harmonized Standard.

With nearly 25 years of developing medical products for Fortune 500 companies, as well as industrial, military and consumer products, Barry has logged over 50,000 hours on SolidWorks, Onshape and MasterCam, 3D Design CAD Software. This experience is complemented by unmatched, hands-on knowledge and proficiency of jurisdictions prototyping and manufacturing processes for product development.

In fact, Barry has played a key role in the successful development of over 100 products in the marketplace today, with a primary focus on medical devices. He is the inventor/co-inventor on numerous patents spanning: mechanical design, assembly and manufacturing for military, industrial, commercial, consumer, and medical product development. Additionally, Barry is expert in Quality Systems Management (13485-2016 and FDA Regulations for design controls CFR 820.30). He specializes in human factors, 3D printing technologies, injection molding, tooling, sheet metal forming, stamping, double-shot molding, molded plastics, polymers, co-polymers, extrusions, rubber, and die casting.

Barry’s connection to Kepley has a somewhat storied past, as Terry E. Brady, now chief inventor at Kepley, engaged John E. Studer, Jr. while Brady was the co-founder of W.T. Associates. Studer is a prolific design maven, who gained industry notoriety for designing the Ortho-McNeil Pharmaceuticals oral contraceptives DialPak®. Studer also developed the initial, streamlined and ergonomic drawings for two of Brady’s products: Surgicutt® - Bleeding Time Device, and Tenderfoot® - Heel Incision Device, both of which have enjoyed over thirty years of market dominance without reengineering. Thereafter, Barry worked alongside Studer for many years, including refining further innovations with Brady when the latter was president of Array Medical.

Surgicutt® and Tenderfoot® are now registered trademarks of Accriva Diagnostics, Inc.

Dr. Sarah Abood earned her Doctor of Veterinary Medicine degree from Michigan State University and her PhD in nutrition from The Ohio State University. Since 2009, she has operated Sit, Stay, Speak Nutrition LLC specializing in nutritional coaching for veterinary health care professionals providing the latest nutrition advances and recommendations for companion animals. Her vast clinical experience in the pet food industry and academic practice, totaling more than 25 years, makes her an expert in the field of animal dietary health.